No Data
No Data
Market Whales and Their Recent Bets on Edwards Lifesciences Options
Express News | Barclays Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $90
Express News | Edward Lifesciences Shares Are Trading Higher, Slightly Rebounding After Falling When the Company Reported Mixed Q3 Results and Issued Weak Guidance This Week. Additionally, Goldman Sachs Maintained a Buy Rating on the Stock
Edwards Lifesciences Is Maintained at Buy by Goldman Sachs
Edwards Lifesciences Price Target Cut to $91.00/Share From $107.00 by Goldman Sachs
Edwards Lifesciences Analyst Ratings
104476495 : hi
104476495 : hi
Josh Massey : Hi
73153837 : Hello.
Mac Giraffe_5465 : It is a sad part to witness Ford’s earnings dropped tremendously despite their strong financial management.
View more comments...